Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and
death. An overactive sympathetic nervous system in CKD patients is one of the major
mechanisms increasing the cardiovascular risks in this patient population. Recently, some
studies have shown that a drug typically used to improve glucose control (pioglitazone) may
also reduce sympathetic nerve activity and improve blood vessel function.
The goal of this study is to determine whether a short-term treatment with pioglitazone can
reduce sympathetic nerve impulses throughout the body in CKD patients.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas at Arlington
Collaborator:
University of Texas, Southwestern Medical Center at Dallas